PriceTargets.com logo

Science 37 - SNCE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.33
  • Forecasted Upside: 483.33%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.40 As of 09/29/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SNCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Science 37 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNCE

Analyst Price Target is $2.33
▲ +483.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Science 37 in the last 3 months. The average price target is $2.33, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 483.33% upside from the last price of $0.40.

This chart shows the closing price for SNCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 4 investment analysts is to moderate buy stock in Science 37. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2023Robert W. BairdLower TargetOutperform$2.00 ➝ $1.00Low
11/14/2022William BlairDowngradeOutperform ➝ Market PerformLow
11/14/2022CowenLower TargetOutperform$7.00 ➝ $3.00Low
11/14/2022CowenLower TargetOutperform$7.00 ➝ $3.00Low
11/11/2022Robert W. BairdLower Target$6.00 ➝ $2.00Low
8/15/2022Craig HallumLower Target$7.00Low
8/15/2022CowenLower Target$7.00Low
8/12/2022Robert W. BairdLower Target$9.00 ➝ $6.00Low
6/7/2022Craig HallumInitiated CoverageBuy$10.00High
4/8/2022Robert W. BairdReiterated RatingBuy$12.00High
11/16/2021Lake Street CapitalBoost TargetBuy$15.00 ➝ $20.00High
11/1/2021Lake Street CapitalInitiated CoverageBuy$15.00High
11/1/2021William BlairInitiated CoverageOutperformHigh
11/1/2021Robert W. BairdInitiated CoverageOutperform$15.00High
10/22/2021CowenInitiated CoverageOutperform$14.00High
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Science 37 logo
Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $0.40
Low: $0.39
High: $0.41

50 Day Range

MA: $0.31
Low: $0.25
High: $0.59

52 Week Range

Now: $0.40
Low: $0.19
High: $1.99

Volume

151,319 shs

Average Volume

217,518 shs

Market Capitalization

$46.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Science 37?

The following Wall Street sell-side analysts have issued stock ratings on Science 37 in the last year: Cowen Inc, Cowen Inc., Robert W. Baird, and William Blair.
View the latest analyst ratings for SNCE.

What is the current price target for Science 37?

3 Wall Street analysts have set twelve-month price targets for Science 37 in the last year. Their average twelve-month price target is $2.33, suggesting a possible upside of 483.3%. Cowen Inc. has the highest price target set, predicting SNCE will reach $3.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $1.00 for Science 37 in the next year.
View the latest price targets for SNCE.

What is the current consensus analyst rating for Science 37?

Science 37 currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SNCE.

What other companies compete with Science 37?

Other companies that are similar to Science 37 include Inotiv, AIkido Pharma, Data Knights Acquisition, Absci and FSD Pharma. Learn More about companies similar to Science 37.

How do I contact Science 37's investor relations team?

Science 37's physical mailing address is 250 W 55TH ST. #3401, NEW YORK NY, 10019. The company's listed phone number is 984-377-3737 and its investor relations email address is investment@lifesciacquisition.com. The official website for Science 37 is www.lifesciacquisition.com. Learn More about contacing Science 37 investor relations.